Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Profit After Tax: 2009-2024

Historic Profit After Tax for Ligand Pharmaceuticals (LGND) over the last 16 years, with Dec 2024 value amounting to -$4.0 million.

  • Ligand Pharmaceuticals' Profit After Tax rose 1735.15% to $117.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year increase of 7.38%. This contributed to the annual value of -$4.0 million for FY2024, which is 107.49% down from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Profit After Tax stood at -$4.0 million for FY2024, which was down 107.49% from $53.8 million recorded in FY2023.
  • In the past 5 years, Ligand Pharmaceuticals' Profit After Tax ranged from a high of $76.4 million in FY2021 and a low of -$33.4 million during FY2022.
  • Its 3-year average for Profit After Tax is $5.5 million, with a median of -$4.0 million in 2024.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Profit After Tax surged by 1,057.21% in 2021, and later crashed by 143.69% in 2022.
  • Over the past 5 years, Ligand Pharmaceuticals' Profit After Tax (Yearly) stood at $6.6 million in 2020, then soared by 1,057.21% to $76.4 million in 2021, then crashed by 143.69% to -$33.4 million in 2022, then spiked by 261.32% to $53.8 million in 2023, then plummeted by 107.49% to -$4.0 million in 2024.